Biren Amin

In a report published Monday, Jefferies analyst Biren Amin initiated coverage on Verastem (NASDAQ: VSTM) with a Buy rating and $21.00 price target. In the report, Jefferies noted, “VSTM's R&D focus is the development of drugs targeting cancer stem cells. VSTM will begin a registration-...

In a report published on Wednesday, Jefferies analyst Biren Amin raised the price target on Celldex Therapeutics (NASDAQ: CLDX) from $15 to $19 and maintained a rating of Buy on the company. In the report, Jefferies stated, "We have included $106M in royalties in 2026 as mgmt could potentially...

In a report published Friday, Jefferies analyst Biren Amin initiated coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy rating and $29.00 price target. In the report, Jefferies noted, “We believe multiple data readouts with potentially positive outcomes over the next 12-18 months offer...